P. Langecker

618 total citations
26 papers, 489 citations indexed

About

P. Langecker is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, P. Langecker has authored 26 papers receiving a total of 489 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 6 papers in Pulmonary and Respiratory Medicine and 6 papers in Cancer Research. Recurrent topics in P. Langecker's work include Estrogen and related hormone effects (5 papers), Cancer Treatment and Pharmacology (4 papers) and Cytokine Signaling Pathways and Interactions (4 papers). P. Langecker is often cited by papers focused on Estrogen and related hormone effects (5 papers), Cancer Treatment and Pharmacology (4 papers) and Cytokine Signaling Pathways and Interactions (4 papers). P. Langecker collaborates with scholars based in United States, Germany and Canada. P. Langecker's co-authors include Richard J. Santen, Paul E. Goss, L. Demers, Susan Ohorodnik, Shuping Wang, Jan Scicinski, Bryan Oronsky, Donna M. Peehl, Gary R. Fanger and Shoucheng Ning and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Journal of Hepatology.

In The Last Decade

P. Langecker

25 papers receiving 476 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
P. Langecker United States 11 152 130 105 94 64 26 489
Per Olov Gunnarsson Sweden 13 152 1.0× 96 0.7× 140 1.3× 85 0.9× 29 0.5× 33 529
Deborah S. White United States 10 198 1.3× 181 1.4× 150 1.4× 54 0.6× 29 0.5× 13 511
Claudia Schurmann Germany 13 116 0.8× 76 0.6× 200 1.9× 66 0.7× 99 1.5× 22 514
José Ortiz United States 8 104 0.7× 36 0.3× 121 1.2× 78 0.8× 49 0.8× 8 398
Kendall W Cradic United States 11 83 0.5× 48 0.4× 203 1.9× 126 1.3× 18 0.3× 19 492
Yongjun Guan China 14 250 1.6× 105 0.8× 364 3.5× 84 0.9× 81 1.3× 34 871
G Kōsaki Japan 15 188 1.2× 62 0.5× 206 2.0× 65 0.7× 64 1.0× 40 685
Edward H. Cooper United Kingdom 14 140 0.9× 46 0.4× 187 1.8× 54 0.6× 59 0.9× 57 722
Faye Turner United Kingdom 13 263 1.7× 58 0.4× 250 2.4× 28 0.3× 41 0.6× 15 529
María I. García Spain 16 322 2.1× 98 0.8× 310 3.0× 33 0.4× 62 1.0× 24 807

Countries citing papers authored by P. Langecker

Since Specialization
Citations

This map shows the geographic impact of P. Langecker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by P. Langecker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites P. Langecker more than expected).

Fields of papers citing papers by P. Langecker

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by P. Langecker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by P. Langecker. The network helps show where P. Langecker may publish in the future.

Co-authorship network of co-authors of P. Langecker

This figure shows the co-authorship network connecting the top 25 collaborators of P. Langecker. A scholar is included among the top collaborators of P. Langecker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with P. Langecker. P. Langecker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hendrickson, Andrea E. Wahner, Nathan R. Foster, Matthew S. Block, et al.. (2024). Phase II clinical trial of PLX038 in patients with platinum resistant ovarian, primary peritoneal and fallopian tube cancer.. Journal of Clinical Oncology. 42(16_suppl). TPS5630–TPS5630. 1 indexed citations
2.
Coveler, Andrew L., Benjamin L. Schlechter, Tanios Bekaii‐Saab, et al.. (2024). A multicenter phase Ia study of AbGn-107, a novel antibody–drug conjugate, in patients with advanced gastrointestinal cancer. Investigational New Drugs. 42(2). 221–228. 1 indexed citations
3.
Sullivan, Ryan J., Filip Jankú, Bob T. Li, et al.. (2017). Abstract CT003: Activity of the ERK1/2 inhibitor ulixertinib (BVD-523) in patients with BRAF and NRAS mutant melanoma. Cancer Research. 77(13_Supplement). CT003–CT003.
4.
Scicinski, Jan, Bryan Oronsky, Shoucheng Ning, et al.. (2015). NO to cancer: The complex and multifaceted role of nitric oxide and the epigenetic nitric oxide donor, RRx-001. Redox Biology. 6. 1–8. 90 indexed citations
5.
Oronsky, Bryan, Corey A. Carter, Tony R. Reid, et al.. (2015). Confirmatory Trials in the Evaluation of Anticancer Medicinal Products in Man—PFS2: A Measure of Therapeutic Action-At-A-Distance. Neoplasia. 17(9). 716–722. 18 indexed citations
6.
Sosa, Julie Ann, Jai Balkissoon, P. Langecker, et al.. (2012). Thyroidectomy followed by fosbretabulin (CA4P) combination regimen appears to suggest improvement in patient survival in anaplastic thyroid cancer. Surgery. 152(6). 1078–1087. 32 indexed citations
7.
Kudrow, David, Lynn R. Webster, John Huddlestone, et al.. (2008). (273) Clinical trial results: A randomized, double-blind, placebo controlled, trial of three-day bupivacaine transdermal patch (ELADUR) in patients with post-herpetic neuralgia. Journal of Pain. 9(4). 44–44. 2 indexed citations
8.
Никитин, И. Г., A. A. Yakovlev, Pavel Bogomolov, et al.. (2007). [11] PHASE 2 STUDY OF OMEGA INTERFERON ALONE OR IN COMBINATION WITH RIBAVIRIN IN SUBJECTS WITH CHRONIC HEPATITIS C GENOTYPE-1 INFECTION. Journal of Hepatology. 46. S8–S8. 16 indexed citations
9.
Santen, Richard J., L. Demers, Susan Ohorodnik, et al.. (2007). Superiority of gas chromatography/tandem mass spectrometry assay (GC/MS/MS) for estradiol for monitoring of aromatase inhibitor therapy. Steroids. 72(8). 666–671. 124 indexed citations
10.
Buckwold, Victor E., Jiayi Wei, Zhuhui Huang, et al.. (2006). Antiviral activity of CHO-SS cell-derived human omega interferon and other human interferons against HCV RNA replicons and related viruses. Antiviral Research. 73(2). 118–125. 32 indexed citations
11.
Buckwold, Victor E., et al.. (2006). Safety Pharmacology, Toxicology and Pharmacokinetic Assessment of Recombinant Human ω‐Interferon Produced from CHO‐SS Cells. Basic & Clinical Pharmacology & Toxicology. 99(1). 62–70. 11 indexed citations
12.
Goss, Paul E., Igor Bondarenko, Kelly Pendergrass, et al.. (2006). Phase 3 study of atamestane + toremifene vs. letrozole in advanced breast cancer. Journal of Clinical Oncology. 24(18_suppl). LBA525–LBA525. 5 indexed citations
13.
Goss, Paul E., et al.. (2005). The effects of atamestane, toremifene, and atamestane plus toremifene compared to letrozole on bone, serum lipids and uterus. Journal of Clinical Oncology. 23(16_suppl). 600–600. 3 indexed citations
14.
Plauth, Mathias, et al.. (2002). Open-label study of omega interferon in previously untreated HCV-infected patients. Journal of Hepatology. 36. 125–125. 5 indexed citations
15.
16.
Schünemann, Holger J., et al.. (1990). Value of bone scanning in the follow-up of breast cancer patients. Journal of Cancer Research and Clinical Oncology. 116(5). 486–491. 6 indexed citations
17.
Santen, Richard J., P. Langecker, Steven J. Santner, et al.. (1990). Potency And Specificity Of CGS-16949A As An Aromatase Inhibitor. Endocrine Research. 16(1). 77–91. 21 indexed citations
18.
Langecker, P., H. Rieß, E Hiller, & W. Wilmanns. (1988). [Heparin-induced thrombocytopenia and thrombosis].. PubMed. 29(7). 515–8. 6 indexed citations
19.
Possinger, K., H. Wagner, P. Langecker, & W. Wilmanns. (1987). Treatment toxicity reduction: breast cancer. Cancer Treatment Reviews. 14(3-4). 263–274. 4 indexed citations
20.
Langecker, P., et al.. (1987). Antikörper gegen Lipoid A in der Behandlung des septischen Schocks. Infection. 15(2). 146–152. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Per Olov Gunnarsson Breakdown of academic impact, for papers by Deborah S. White Breakdown of academic impact, for papers by Claudia Schurmann Breakdown of academic impact, for papers by José Ortiz Breakdown of academic impact, for papers by Kendall W Cradic Breakdown of academic impact, for papers by Yongjun Guan Breakdown of academic impact, for papers by G Kōsaki Breakdown of academic impact, for papers by Edward H. Cooper Breakdown of academic impact, for papers by Faye Turner Breakdown of academic impact, for papers by María I. García
Rankless by CCL
2026